Florida Feasibility Study Tests AI-Driven Precision Medicine Platform for Refractory Cancer Patients — xDRIVE Trial Opens

References

1. 1.First Ascent Biomedical Inc. (2024). xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed/Refractory Cancers. ClinicalTrials.gov. NCT07167381. https://clinicaltrials.gov/study/NCT07167381
2. 2.Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015). Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 15(12), 747-756. https://doi.org/10.1038/nrc4015
3. 3.Letai, A. (2017). Functional precision cancer medicine—moving beyond DNA sequencing to functional tumor profiling. Nature Medicine, 23(10), 1208-1215. https://doi.org/10.1038/nm.4389
4. 4.Pemovska, T., Kontro, M., Yadav, B., Edgren, H., Eldfors, S., Szwajda, A., ... & Heckman, C. A. (2013). Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery, 3(12), 1416-1429. https://doi.org/10.1158/2159-8290.CD-13-0350
5. 5.Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 233-254. https://doi.org/10.3322/caac.21763
6. 6.Tannock, I. F., & Hickman, J. A. (2016). Limits to personalized cancer medicine. New England Journal of Medicine, 375(13), 1289-1294. https://doi.org/10.1056/NEJMra1510065
7. 7.Zavala, V. A., Bracci, P. M., Carethers, J. M., Carvajal-Carmona, L., Coggins, N. B., Cruz-Correa, M. R., ... & Fejerman, L. (2021). Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 124(2), 315-332. https://doi.org/10.1038/s41416-020-01038-6